Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2007-01-23
2007-01-23
Spivack, Phyllis G. (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
10969885
ABSTRACT:
A method for promoting myelination of an axon comprising administering 4-[α-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid is disclosed.
REFERENCES:
patent: 2235621 (1997-05-01), None
patent: 195 41 146 (1997-04-01), None
patent: 0 881218 (1998-12-01), None
Mineo Tsuruta et al., “Tromboxane; Gosei Kouso Sogaizai (No. 1)”,Yakugaku Zasshi, vol. 109, No. 1, pp. 33-45 (1989).
Andrew P. Mizisin et al., “Myelin splitting, Schwann cell injury and demyelination in feline diabetic neuropathy”, Acta Neuropathol, 95, pp. 171-174, 1998.
G. Said et al., “Uncommon early-onset neuropathy in diabetic patients”, Journal of Neurology, vol. 245, No. 2, pp. 61-68, XP002299181, Feb. 1998.
Gotoh Nobuharu
Hayashi Yoshiharu
Kawasaki Kazuyuki
Kawasaki Masakazu
Mitsubishi Pharma Corporation
Spivack Phyllis G.
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
MAG expression promoters does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with MAG expression promoters, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and MAG expression promoters will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3754823